These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16220110)

  • 21. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
    Zand N; Tajik N; Moghaddam AS; Milanian I
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
    Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
    Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
    Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
    Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
    Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
    Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
    Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
    Hung CC; Huang HC; Gao YH; Chang WL; Ho JL; Chiou MH; Hsieh YW; Liou HH
    Pharmacogenomics; 2012 Sep; 13(12):1339-49. PubMed ID: 22966884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.